Newly discovered proteins may prevent progression to end-stage renal disease in diabetes miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Photo by SCIEPRO/Getty Images
Clinical diagnostic company Renalytix AI has expanded its partnership with the Joslin Diabetes Center to integrate new biomarkers for kidney disease discovered by the center s researchers into the company’s KidneyIntelX platform.
KidneyIntelX is an in vitro diagnostic platform that assesses the risk of adverse kidney outcomes in patients with Type 2 diabetes and early-stage kidney disease. By examining a patient’s blood sample and medical history, the diagnostic generates a risk score for disease progression. Physicians can use the risk score to predict the progression of chronic kidney disease (CKD) and to guide treatments to help prevent kidney-function decline.
surrounding a comprehensive panel of novel biomarkers in kidney disease NEW YORK, April 14, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announced today that it has entered into an exclusive option agreement with Joslin Diabetes Center for patent filings on certain additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX in vitro prognostic platform. These novel biomarkers have the potential to provide additional clinical utility for understanding early disease progression and risk of kidney failure, therapeutic response, and the mechanistic pathways of kidney disease beyond the inflammatory and tubular injury markers that are currently captured by KidneyIntelX. RenalytixAI plans to begin evaluating these novel biomarkers in expanded clinical validation studies beginning in the second half of 2021.